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ABSTRACT 
Background: ART adherence is critical for successful HIV treatment outcomes. Once-daily dosing 
could improve adherence. Plasma concentrations of once- vs twice-daily abacavir+lamivudine are 
bioequivalent in children, but no randomised trial has compared virological outcomes.  
Methods: Children taking abacavir+lamivudine-containing first-line regimens twice-daily for >36 
weeks in the ARROW trial (NCT02028676,ISRCTN24791884) were randomised to continue twice-
daily versus move to once-daily abacavir+lamivudine (open-label). Co-primary outcomes were viral 
load (VL) suppression at week-48 (12% non-inferiority margin, measured retrospectively) and 
lamivudine or abacavir-related grade 3/4 adverse events (AEs).  
Results: 669 children (median 5 years, range 1-16) were randomised to twice-daily (n=333) vs once-
daily (n=336) after median 1.8 years on twice-daily abacavir+lamivudine-containing first-line ART. 
Children were followed for median 114 weeks. At week-48, 242/331 (73%) twice-daily vs 236/330 
(72%) once-daily had VL<80c/ml (difference -1.6% [95% CI -8.4%,+5.2%] p=0.65); 79% twice-daily vs 
78% once-daily had VL<400c/ml (p=0.76) (week-96 results similar). One grade 3/4 AE was judged 
uncertainly related to abacavir+lamivudine (hepatitis; once-daily). At week-48, 9% twice-daily vs 10% 
once-daily reported missing one or more ART pills in the last 4 weeks (p=0.74), and 8% vs 8% at 
week-96 (p=0.90). Carers strongly preferred once-daily dosing. There was no difference between 
randomised groups in post-baseline drug-resistance mutations or drug-susceptibility; WHO 3/4 
events; ART-modifying, grade 3/4 or serious AEs; CD4% or weight/height-for-age (all p>0.15). 
Conclusions: Once-daily abacavir+lamivudine was non-inferior to twice-daily in VL suppression, with  
similar resistance, adherence, clinical, immunological and safety outcomes. Abacavir+lamivudine 
provides the first once-daily nucleoside backbone across childhood that can be used to simplify ART.  
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INTRODUCTION 
In 2014, 740,000 HIV-infected children were receiving antiretroviral therapy (ART), the vast majority 
in Sub-Saharan Africa[1]. However, this was only 32% of those living with HIV and approximately 
220,000 children became newly HIV-infected in 2014. HIV-infected children need life-long treatment, 
which requires optimal adherence[2]. Once-daily medication is one strategy for promoting this[3]. 
The World Health Organisation (WHO) preferred first-line ART is two nucleoside-reverse-
transcriptase-inhibitors (NRTIs), abacavir and lamivudine, and a third drug, either a non-nucleoside-
reverse-transcriptase-inhibitor (NNRTI) in those >3 years or a boosted-protease-inhibitor (bPI) in 
those <3 years[4]. The once-daily lamivudine+abacavir fixed-dose-combination was licensed in adults 
and adolescents >12 years in 2005 based on three large randomised efficacy trials[5-7], but 
regulators did not licence paediatric once-daily dosing. This was despite pharmacokinetic 
bioequivalence among African children aged 3-12 years[8], with similar results in European children 
aged 3-<36months[9] and 2-13 years[10], and despite carers reporting  high acceptability and strong 
preference for once-daily dosing[11]. Lamivudine and abacavir therefore largely continued to be 
used twice-daily for children <12 years. 
 
Non-randomised studies among children in Europe[10, 12, 13], and randomised and non-
randomised studies in adults[3, 6, 14-17], have reported favourable clinical, immunological, 
virological, safety, adherence and acceptability outcomes over 24–48 weeks for regimens containing 
once-daily abacavir and/or lamivudine[3, 6, 9, 10, 13-15, 17]. We therefore randomised Ugandan/ 
Zimbabwean children enrolled in the ARROW trial[18] to once versus twice-daily 
lamivudine+abacavir and compared treatment outcomes and adherence over 96 weeks.  
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METHODS 
This was an open randomized parallel-group trial within the ARROW trial 
(NCT02028676,ISCRTN24791884)[18] conducted at three centres in Uganda and one in Zimbabwe. 
The main trial recruited previously untreated HIV-infected children/adolescents who were 
randomised to initiate ART using standard lamivudine+abacavir+NNRTI or a 36-week induction-
maintenance approach (Supplementary Figure 1). Children were also randomised factorially to 
routine laboratory plus clinical monitoring (LCM) or  clinically driven monitoring (CDM). This trial co-
enrolled ARROW children on twice-daily lamivudine+abacavir-containing first-line ART for >36 weeks 
and expected to stay on this regimen for at least 12 weeks. Participants were randomized 1:1 to 
continue twice-daily versus move to once-daily lamivudine+abacavir. The hypothesis was that once-
daily dosing would result in similar outcomes to twice-daily in children on long-term ART (non-
inferiority). Caregivers and older children (18 years) gave written consent; those 7-18 years gave 
assent (depending on knowledge of HIV status). The trial was approved by Research Ethics 
Committees in Uganda, Zimbabwe and the UK.  
 
Abacavir and lamivudine were dosed following WHO guidelines, and taken as single drugs (tablets or 
solutions) or co-formulated as Kivexa (tablets), depending on other drugs in the regimen (efavirenz, 
nevirapine or zidovudine following original ARROW factorial randomisation to 
lamivudine+abacavir+NNRTI continuously (Arm-A); induction-maintenance with 4-drug 
lamivudine+abacavir+NNRTI+zidovudine for 36 weeks, followed by lamivudine+abacavir+NNRTI 
(Arm-B) or lamivudine+abacavir+zidovudine (Arm-C; 3NRTI)). The NNRTI (nevirapine/efavirenz) was 
chosen by clinicians according to local availability (varying by country) and age. Throughout 
“abacavir+lamivudine” denotes either combined single tablets or the fixed-dose-combination.  
 
Randomization was stratified by centre, and the two factorial randomizations within the main 
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ARROW trial. The computer-generated sequentially numbered randomization list (variable block 
sizes) was pre-prepared by the Trial Statistician and incorporated securely into the trial database at 
each centre, concealed from local staff. Allocation was made after eligibility was confirmed by local 
centre staff who then performed the randomisation. 
 
Children were reviewed at nurse visits every 6 weeks using a standard symptom checklist, with ART 
and cotrimoxazole adherence assessed by self-reported questions about when doses were last 
missed. They saw a doctor and had full blood count, CD4, liver and renal function tests (bilirubin, 
urea, creatinine, AST, ALT) at randomization and then every 12 weeks. All laboratory test results 
were routinely returned for children randomized to LCM, but no CD4s were returned for children 
randomised to CDM, and haematology/biochemistry were returned only if needed for clinical 
management. Toxicity substitutions and/or switch to bPI-containing second-line regimens were at 
the treating physician’s discretion, following WHO guidelines. Viral loads (VL) were  not measured in 
real-time and not used for management. Participants continued follow-up until ARROW trial closure 
(16 March 2012).  
 
VL was assayed retrospectively on stored plasma samples at 0, 48 and 96 weeks after randomisation 
using the Abbott m2000rt with 2:1 dilution as many samples had small volumes, leading to a lower 
limit of detection of 80 c/ml (rather than 40 c/ml). Samples >1000 copies/ml were genotyped using 
in house primers (Supplementary Table 1) at the Joint Clinical Research Centre using an automated 
ABI 3730xl sequencer; where original samples had been exhausted or failed repeatedly, 
replacements up to 24 weeks before baseline, or within ±18 weeks of weeks 48/96 were assayed. VL 
assays and genotyping was performed blinded to randomization. Subtype was predicted using REGA 
v3.0, drug-resistance mutations defined using IAS-USA 2013[19], and drug susceptibility predicted 
using Stanford v7, using the full sequence data[20]. 
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Carers of children randomised to once-daily completed an acceptability questionnaire about giving 
twice-daily medication and their views about changing to once-daily administration immediately 
after randomisation. An equivalent questionnaire asking about actual experiences of once-daily 
administration was completed 12 and 48 weeks later (see Table 2 for specific questions).  
 
Co-primary endpoints were VL at week-48 (pre-specified 12% non-inferiority margin for suppression 
regardless of threshold) and lamivudine or abacavir-related grade 3/4 adverse events (AEs). 
Secondary endpoints included: VL at week-96; resistance; change in absolute and percentage CD4; 
WHO stage 3/4 event/death; WHO stage 4 event/death; mortality; hospitalisations; weight- and 
height-for-age; grade 3/4 AEs; serious adverse events (SAEs); ART-modifying AEs; switch to second-
line ART; and ART adherence (self-reporting any missed ART doses in the last 4 weeks). Clinical 
events and SAEs were reviewed by an Endpoint Review Committee with independent chair and 
members, blinded to randomization. 
 
631 children provided 90% power to establish non-inferiority of once-daily vs twice-daily 
lamivudine+abacavir, defined as the upper 95% confidence limit for the difference in suppression 
(once- minus twice-daily) of no more than 12% (recommended by Food and Drug Administration), 
assuming 70% suppression on twice-daily and 15% missing VLs due to missing samples, missed visits, 
death, or loss to follow-up. Interim data were reviewed annually by an independent Data Monitoring 
Committee.  
 
Statistical Analysis 
All comparisons are intention-to-treat; no per-protocol analyses were pre-specified and none were 
performed given the high compliance with randomised allocation. p-values presented test the null 
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hypothesis of no difference (superiority) between randomized groups; absolute unadjusted 
differences in percentages (with exact 95% CI) were estimated using Poisson regression to address 
the original non-inferiority hypothesis. Subgroup analyses of VL <80 c/ml and <400 c/ml were 
conducted by key baseline characteristics including sex, age, centre, CD4-for-age, weight-for-age, 
year of randomisation, CD4 monitoring randomisation, ART regimen and formulation using Poisson 
regression (all pre-specified in the Statistical Analysis Plan except for formulation which was 
exploratory). Secondary outcomes were compared between randomized groups using log-rank tests 
for time-to-event outcomes and generalised estimating equations with independent working 
correlation for global tests of repeated measures (normal distribution for CD4 and weight/height-
for-age; logistic distribution for missing doses in the last 4 weeks (adherence)). Self-reported 
responses to acceptability questions were compared across timepoints using matched-pairs sign-
rank tests. 
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RESULTS 
Between 19 August 2009 and 29 June 2010, 732 eligible children were approached; 669 (91%) 
consented and were randomised to continue twice-daily (n=333) or move to once-daily (n=336) 
lamivudine+abacavir (Supplementary Figure 2). Main reasons for not consenting were reluctance to 
change from current twice-daily ART (n=21) and worries about forgetting doses on once-daily 
regimens (n=20). Median age was 5.5 years (range 1.8–16.9) and 52% were girls; participants had 
spent a median 1.8 years (range 0.9–3.0) on twice-daily abacavir+lamivudine containing first-line 
ART, which they were receiving with nevirapine (48%), efavirenz (18%) or zidovudine (34%). Baseline 
characteristics were similar in twice-daily and once-daily groups (Table 1). 
 
Median follow-up was 114 weeks (IQR 106-125; range 48-134). 7 children were lost (last seen before 
March 2012; 3 twice-daily, 4 once-daily), of whom 4 formally withdrew consent (Supplementary 
Figure 2). A further 5 children died, all >48 weeks after randomisation (none drug-related; 4 twice-
daily (presumptive pulmonary tuberculosis, pneumonia, cor pulmonale, cause unknown), 1 once-
daily (lung-related, specific condition unknown)). After randomisation, 98% vs 97% child-time was 
spent on twice-daily vs once-daily abacavir+lamivudine in the two groups respectively. 29(4%) 
children (11 twice-daily, 18 once-daily) ever moved off their allocated dosing strategy, of whom 13 
(6 twice-daily, 7 once-daily) switched to bPI-containing second-line ART. Five carers in the once-daily 
group requested a return to twice-daily, and two carers in the twice-daily group requested once-
daily (Supplementary Figure 2). 
 
Not all children were virologically suppressed at randomisation (Table 1) because VLs were only 
tested retrospectively at trial closure. By chance, at randomisation (week 0) there was a small non-
significant excess of 3-5% in the percentages >80, >400 and >1000 c/ml in the once-daily group 
(Figure 1): this had attenuated by week 48 and 96 when VL suppression at all thresholds was very 
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similar in twice-daily and once-daily groups and within ±10% (and thus well within the 12% non-
inferiority margin). In particular, 242/331 (73%) twice-daily vs 236/330 (72%) once-daily participants 
were <80 c/ml at 48 weeks (difference -1.6% [95% CI -8.4%,+5.2%] p=0.65), and 234/326 (72%) vs 
230/331 (69%) respectively at 96 weeks (difference -2.3% [-9.3%,+4.7%] p=0.52). 
 
There was no evidence of heterogeneity in the difference between once-daily vs twice-daily 
administration in suppression <80 c/ml or <400 c/ml at 48 or 96 weeks according to CD4 monitoring 
(LCM/CDM), sex, age (Figure 2(a)), VL at randomisation (Figure 2(b)) or formulation (p>0.12). By 
chance, at randomisation more children on lamivudine+abacavir+efavirenz randomised to once-
daily, and fewer children on 3NRTI randomised to once-daily, were suppressed (<400 c/ml 
heterogeneity p=0.04). These differences persisted through 48 and 96 weeks (both heterogeneity 
p=0.01; Figure 2(c); similar results for <80 c/ml). Overall 86% of children on the current WHO-
preferred first-line regimen of once-daily/twice-daily lamivudine+abacavir+NNRTI were <400 c/ml at 
48 weeks.  
 
There was no evidence that the relative effect of once-daily vs twice-daily administration on VL 
suppression varied by age (Figure 2(a), p>0.5), but univariably suppression appeared lower in 
younger and older children in both groups. Multivariable logistic models for VL <400 c/ml at 48 
weeks including all factors considered in subgroup analyses and centre found that this was partly 
due to confounding, with a trend towards poorer VL suppression with syrups than tablets (adjusted 
odds ratio (OR) (tablets:syrups)=2.55 [95% CI 0.89-6.39] p=0.08). Adjusting for formulation, 
suppression was then significantly poorer only in older children (OR per year older=0.79 [0.70,0.88] 
p<0.0001), as well as those not receiving efavirenz (OR(3NRTI:efavirenz)=0.20 [0.07,0.29] p=0.001, 
OR(nevirapine:efavirenz)=0.29 [0.10,0.81] p=0.02), and those with higher baseline VL (p<0.001).  
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Of 114, 134 and 135 children with VL >1000 c/ml at weeks 0, 48 and 96 respectively, genotypes were 
obtained in 105 (92%), 129 (96%) and 130 (96%) (p>0.3 comparing twice- vs once-daily). Overall 179 
(49%) genotypes were subtype-A, 90 (25%) subtype-C (including all Zimbabwean children) and 72 
(20%) subtype-D. Only 6 (6%), 4 (3%) and 4 (3%) children had at most low-level resistance to all 
NRTIs and NNRTIs at weeks 0, 48 and 96 respectively, suggesting non-adherence. There was no 
evidence of differences between twice-daily and once-daily groups in intermediate/high-level NRTI 
resistance, or specific NRTI mutations, at any timepoint (p>0.15, Figure 3, Supplementary Figure 3). 
Modest differences between randomised groups in intermediate/high-level NNRTI resistance at 
week 48, but not week 96, appeared to persist from baseline (Figure 3). In the subgroup of children 
receiving the current WHO preferred regimen of abacavir+lamivudine+NNRTIs (twice- or once-daily), 
in whom second-line NRTI options would be zidovudine or tenofovir, intermediate/high-level 
resistance 0/48/96 weeks after randomisation was 15%/16%/8% for tenofovir and 0%/4%/2% for 
zidovudine, compared to 75%/84%/79% for abacavir (N≥48). In the subgroup of children receiving 
3NRTIs, intermediate/high-level resistance was similar to those on abacavir+lamivudine+NNRTIs for 
abacavir (71%/77%/79% 0/48/96 weeks after randomisation respectively, p>0.3 vs 
abacavir+lamivudine+NNRTIs), greater for tenofovir (28%/50%/54% respectively; p<0.001 at weeks 
48 and 96) and greater for zidovudine (64%/74%/73% respectively, p<0.001) (N≥58). 
 
As expected, M184V/I mutations were common in both groups (supplementary Figure 3). In the 
subgroup of children receiving abacavir+lamivudine+NNRTIs (twice- or once-daily) 74V and 115F 
mutations were observed in 56%/64%/70% and 56%/62%/68% respectively at weeks 0/48/96; but 
these were much less frequent in children receiving 3NRTIs (3%/3%/3% and 16%/20%/19% 
respectively; all p<0.001 versus abacavir+lamivudine+NNRTIs). As expected, thymidine-analogue 
mutations (TAMs) were rarely seen in children on abacavir+lamivudine+NNRTIs. Children had a 
median (IQR) 3 (2-3), 3 (2-4) and 3 (2-4) NRTI mutations at weeks 0, 48, and 96 respectively 
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suggesting slow accumulation of additional mutations (p>0.3 comparing twice- vs once-daily): only 6 
(6%), 8 (6%) and 6 (5%) children had K65R mutations respectively (6/7/3 on 
abacavir+lamivudine+NNRTI, 0/1/3 on 3NRTI). Q151M was seen in one child on once-daily 3NRTIs at 
both week 48 and 96 (both also with K65R). There was no evidence of difference (p>0.05) between 
twice-daily vs once-daily in the change in NRTI Stanford score in 87 children with paired genotypes at 
weeks 0 and 48 (p>0.1; >62% had no change in score), in 80 children with paired genotypes at weeks 
0 and 96 (p>0.1; >56% had no change in score), or in 101 children with paired genotypes at weeks 48 
and 96 (p>0.1;>69% had no change in score) with the exception of abacavir, where if anything, 
Stanford score increased more in the twice-daily group (p=0.045; 87% had no change in score). 
 
Self-reported adherence was similar in the two groups: at 48 weeks, 29/330 (9%) twice-daily vs 
32/336 (10%) once-daily reported missing one or more ART pills in the last 4 weeks (p=0.74), and 
25/309 (8%) vs 26/311 (8%) respectively at 96 weeks (p=0.90) (global p=0.93 across 6-120 weeks, 
Supplementary Figure 4). There was no evidence that differences in self-reported adherence 
between twice-daily and once-daily randomised groups varied across the different third 
antiretrovirals (heterogeneity p=0.38).  
 
Acceptability questionnaires were completed by 312 (93%), 274 (82%) and 277 (82%) carers 0, 12 
and 48 weeks after randomisation to once-daily lamivudine+abacavir (Table 2). At randomisation, 
16% of carers reported that timing of twice-daily medication had sometimes/always been a 
problem: this reduced significantly to 4% after 12 weeks on once-daily (signrank p<0.001). Problems 
with taste on twice-daily dosing also reduced significantly following move to once daily (8% vs 3% 
respectively, signrank p=0.003). 78% of carers anticipated that moving to once-daily would make 
things a lot/little easier for them, expectations that were largely realised (83% and 81% at weeks 12 
and 48). Fewer (65%) thought moving to once-daily would make things a lot/little easier for the 
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child, but again these expectations were realised. Many who felt moving to once-daily 
lamivudine+abacavir had made no difference commented this was because other drugs were still 
taken twice daily: however, others commented that even giving some drugs once-daily improved 
administration because the second dose was smaller. Overall carers expressed strong preferences 
for once-daily administration (98%, 98% and 96% preferring this at weeks 0, 12 and 48 respectively). 
In contrast to high-income countries, approximately 50% of carers gave once-daily medication in the 
morning. Comments related to the flexibility of once-daily dosing fitting around work schedules and 
different places where the child stayed (median two individuals gave drugs to the child); and also to 
administering medication taking less total time out of the day. Several carers of children on once-
daily medication noted that both they and the child now took their drugs together helping them to 
remember. 
 
There was no difference between groups in all grade 3/4 or serious AEs, WHO 3/4 events, weight-
for-age, height-for-age, CD4% or CD4 in those >5 years (all p>0.15). 54 (16%) twice-daily vs 57 (17%) 
once-daily had one or more grade 3/4 AEs (p=0.82): most commonly asymptomatic neutropenia 
(n=38) and malaria (n=32). 37 (11%) twice-daily vs 30 (9%) once-daily had one or more SAEs 
(p=0.31). 14 (4%) twice-daily vs 18 (5%) once-daily had one or more grade 4 AEs (p=0.48). 7 (2%) 
twice-daily vs 3 (1%) once-daily had new WHO 4 stage events or died (p=0.20), and 12 (4%) vs 9 (3%) 
respectively had new WHO 3 or 4 stage events or died (p=0.51). One grade 3/4 adverse event 
(hepatitis) was judged uncertain whether related to abacavir+lamivudine (once-daily group) (no 
events judged definitely/probably related). There were no AEs directly leading to abacavir or 
lamivudine modification. There were no reported hypersensitivity reactions. Increases in CD4% in 
twice-daily vs once-daily were +1.3% vs +0.9% at 48 weeks (p=0.39), and +2.5% vs +1.6% at 96 weeks 
(p=0.12). 
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DISCUSSION 
Among a large group of HIV-infected children in the ARROW trial[18], over a median 2.2 years of 
follow-up, we observed comparable viral suppression between children randomised to once- daily 
versus twice-daily dosing of lamivudine+abacavir, with no difference in all grade 3/4 or serious 
adverse events. Our findings strengthen the evidence from previous smaller and shorter 
pharmacokinetic studies among children in Europe[9, 10], and formed the basis for recent US and 
European licencing of lamivudine and abacavir once-daily for children >3 months of age. This is 
particularly important now that lamivudine+abacavir is the preferred NRTI backbone in the WHO 
2013 and 2015 consolidated ART guidelines[4], with several countries in Sub-Saharan Africa adopting 
the recommendation, enabling the first once-daily 2NRTI+NNRTI regimen for children.  
 
Whilst we did not observe differences  in adherence between once- and twice-daily dosing in this 
randomised trial, either overall or in subgroups defined by the ART regimen (Supplementary Figure 
4), the majority of children were taking lamivudine+abacavir with nevirapine or zidovudine, meaning 
they were still taking ART twice daily. Power to detect improvements in adherence with once-daily 
ART was low within the smallest subgroup taking once-daily lamivudine+abacavir+efavirenz. 
Simplifying ART regimens with completely once-daily dosing would be expected to lead to improved 
adherence with potentially favourable treatment outcomes[3], that are particularly important in 
children who need to take ART lifelong. Acceptability questionnaires demonstrated strong 
preferences from carers for once-daily dosing as a mechanism to improve adherence. Once-daily 
single tablet regimens (STR) which minimise the number of pills and daily doses have been 
associated with improved adherence and better quality of life in adults[21]. The most widely used 
STR among adults is a combination of tenofovir, emtricitabine or lamivudine, and efavirenz; although 
tenofovir is licensed in children over 2 years[22], it is not recommended as the preferred agent in 
children under 10 years by WHO. However, abacavir has been safely used among African children, 
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with very low rates of hypersensitivity (0.3%)[18, 23]. Thus an abacavir-based paediatric STR may be 
more favourable in Sub-Saharan Africa and other low/middle-income settings, potentially combined 
with the NNRTIs efavirenz or rilpivirine; integrase inhibitors (cobicistat-boosted elvitegravir or 
dolutegravir); and protease inhibitors (cobicistat-boosted darunavir)[24]. 
 
The major concern about once-daily dosing, which had not been demonstrated in adult trials from 
high-income countries[5-7], was that it could be more “fragile”; namely, if a child missed one dose 
when taking lamivudine+abacavir twice-daily they still got some drug, whereas if they missed one 
dose when taking lamivudine+abacavir once-daily they missed drugs for the whole day, potentially 
leading to lower VL suppression and/or greater accumulation of drug-resistance mutations. As well 
as not observing any difference in VL suppression between twice-daily and once-daily dosing, we 
also observed no differences in drug-resistance mutations, predicted drug susceptibility or 
accumulation of resistance among 364 sequences. Whilst the fact that most children were taking 
their third antiretroviral twice-daily could theoretically have protected them from viral 
breakthrough, once replicating virus was present any increased fragility of once-daily 
lamivudine+abacavir should have been apparent. The fact that this was not observed is therefore re-
assuring, particularly given the limited virological monitoring available in many low-income 
countries. 
 
The main trial limitations relate to its opportunistic incorporation within an ongoing trial, although 
this also provided substantial efficiency gains. The trial was open-label, although the primary 
endpoint (VL suppression) was assayed retrospectively blinded to randomisation. Children received 
different third antiretrovirals with lamivudine+abacavir; although this increased generalisability, 
different third drugs (zidovudine (in  a triple NRTI regimen) vs NNRTI) exerted very different selective 
pressures, necessitating subgroup analysis of resistance with smaller numbers than overall. Some 
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children also remained on a twice-daily regimen because of other drugs, meaning that potential 
improvements in VL suppression with completely once-daily regimens could be masked. Also the 
same formulation could not be used for all age groups. However, this allowed us to identify that the 
younger children taking syrups were less likely to have virological suppression, similarly to the trial as 
a whole[23], potentially explained by increased complexity of dosing with syrups, lower 
bioavailability of lamivudine syrup[25, 26], and a general preference for tablets by the younger 
children and their caregivers[27]. Randomisation did not occur at ART initiation, but after children 
had received a median 1.8 years first-line ART; recommending once-daily administration from ART 
initiation is therefore an extrapolation, although there was no evidence that children who happened 
to not be virologically suppressed at randomisation did worse on once- vs twice daily. 
 
In summary, once-daily dosing of the WHO-preferred NRTI backbone lamivudine+abacavir was non-
inferior to twice-daily dosing in terms of virological suppression, resistance and adherence, as well as 
clinical, immunological, and safety outcomes. It was strongly preferred by almost all carers. 
Lamivudine+abacavir is therefore the first dual NRTI regimen which can be used once-daily across 
the entire age-range to improve acceptability and long-term adherence among HIV-infected 
children, and also provides the potential for several different paediatric single-tablet once-daily 
regimens in future.  
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Table 1 Characteristics at randomisation to once-daily vs twice-daily lamivudine+abacavir 
 Twice daily 
(n=333) 
Once daily 
(n=336) 
Total 
(n=669) 
Centre Entebbe, Uganda 
 Joint Clinical Research Centre, Uganda 
 Baylor-Mulago, Uganda 
 Harare, Zimbabwe 
65 (20%) 
74 (22%) 
87 (26%) 
107 (32%) 
65 (18%) 
77 (23%) 
87 (24%) 
107 (32%) 
130 (19%) 
151 (23%) 
174 (26%) 
214 (32%) 
Girls 172 (52%) 173 (51%) 345 (52%) 
Age (years) 5.1 (3.6-8.3) 5.9 (2.8-8.6) 5.5 (3.7-8.5) 
Pre-ART CD4% 12.5 (8.5-18.0) 13.0 (8.5-18.9) 13.0 (8.5-18.0) 
Pre-ART CD4 if >5 years at ART initiation 
(cells/mm3) 
263 (124-404) 301 (136-416) 278 (136-410) 
Years since ART initiation 1.8 (1.4-2.3) 1.8 (1.4-2.1) 1.8 (1.4-2.1) 
Current CD4%  33 (27-39) 33 (28-39) 33 (28-39) 
Current CD4 if >5 years at ART initiation 
(cells/mm3) 
836 (558-1131) 760 (543-1136) 812 (557-1134) 
Current weight-for-age Z-score -1.3 (-2.0,-0.6) -1.4 (-2.0,-0.7) -1.4 (-2.0,-0.7) 
Current WHO stage (worst ever): 
 1/2 
 3 
 4 
 
96 (29%) 
185 (56%) 
52 (16%) 
 
73 (22%) 
209 (62%) 
54 (16%) 
 
169 (25%) 
394 (59%) 
106 (16%) 
Current VL *: 
 <80 c/ml 
 <400 c/ml 
 <1000 c/ml 
 
250 (76%) 
272 (82%) 
281 (85%) 
 
237 (71%) 
266 (79%) 
271 (81%) 
 
487 (73%) 
538 (81%) 
552 (83%) 
ART regimen  
 Lamivudine+abacavir+nevirapine† 
 Lamivudine+abacavir+efavirenz 
 Lamivudine+abacavir+zidovudine† ** 
 Lamivudine+abacavir+stavudine† ** 
 
171 (51%) 
49 (15%) 
112 (34%) 
1 (0.3%) 
 
148 (44%) 
73 (22%) 
115 (34%) 
0 
 
319 (48%) 
122 (18%) 
227 (34%) 
1 (0.1%) 
ART formulation 
 Any syrup 
 All tablets 
 
26 (8%) 
307 (92%) 
 
30 (9%) 
306 (91%) 
 
56 (8%) 
613 (92%) 
CD4 monitoring (LCM) 
No CD4 monitoring (CDM) 
159 (48%) 
174 (52%) 
163 (49%) 
173 (51%) 
322 (48%) 
347 (52%) 
* Tested retrospectively; missing 2 twice-daily, 1 once-daily (repeated assay failure)  
** 3NRTI maintenance following 4-drug induction as part of main ARROW factorial randomisation.  
† nevirapine, zidovudine, and stavudine continued to be given twice-daily. 
Note: values are n (%)or median (IQR).  
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Table 2 Acceptability of move from twice-daily to once-daily lamivudine+abacavir 
 Week 0 
(random-
isation)  
Week 12 Week 48 P 
0vs12* 
P 
0vs48* 
Acceptability form completed (N=336) 312 (93%) 274 (82%) 277 (82%) - - 
Number of people giving medicines to the child, 
median (IQR) 
2 (1-2) 2 (1-2) 2 (1-2) - - 
Timing of twice-daily (week 0) or once-daily (week 
12/48) medication: sometimes or always a problem 
50 (16%) 11 (4%) 8 (3%) <0.001 <0.001 
Number of twice-daily (week 0) or once-daily (week 
12/48) medicines: sometimes or always a problem 
14 (5%) 5 (2%) 5 (2%) 0.29 0.03 
Taste of twice-daily (week 0) or once-daily (week 
12/48) medication: sometimes or always a problem 
25 (8%) 7 (3%) 9 (3%) 0.003 0.002 
How switching to once-daily will be (week 0)/was 
(week 12/48) for the carer 
 A lot easier 
 A little easier 
 No difference 
 A little more difficult 
 
 
187 (60%) 
55 (18%) 
65 (21%) 
4 (1%) 
 
 
172 (63%) 
55 (20%) 
44 (16%) 
2 (1%) 
 
 
147 (53%) 
77 (28%) 
49 (18%) 
3 (1%) 
0.004 0.64 
How switching to once-daily will be (week 0)/was 
(week 12/48) for the child 
 A lot easier 
 A little easier 
 No difference 
 A little more difficult 
 A lot more difficult 
 
 
139 (45%) 
61 (20%) 
104 (34%) 
4 (1%) 
2 (1%) 
 
 
99 (37%) 
72 (27%) 
94 (35%) 
5 (2%) 
1 (0.4%) 
 
 
92 (34%) 
83 (31%) 
94 (35%) 
3 (1%) 
0 
0.16 0.44 
Do you think it will be (week 0)/is (week 12/48) 
easier to give all medicines once daily 
 No 
 Yes 
 Not sure 
 
 
4 (1%) 
285 (93%) 
19 (6%) 
 
 
6 (2%) 
253 (93%) 
13 (5%) 
 
 
3 (1%) 
250 (91%) 
23 (8%) 
0.22 0.34 
Overall, which do you think (week 0)/do you (week 
12/48) prefer? 
 Once-daily 
 Twice-daily 
 
 
305 (98%) 
6 (2%) 
 
 
268 (98%) 
6 (2%) 
 
 
265 (96%) 
11 (4%) 
0.74 0.13 
What time will you (week 0)/do you (week 12/48) 
give once-daily medicines 
 Morning 
 Evening 
 
 
148 (48%) 
163 (52%) 
 
 
122 (45%) 
151 (55%) 
 
 
137 (50%) 
139 (50%) 
0.46 0.72 
Ever reported going back to giving medicines twice-
daily? 
- 6 (2%) 21 (8%) - - 
* signrank test comparing 257 carers with questionnaires at weeks 0 and 12, and 0 and 48. 
Note: at week0 (randomisation) carers were asked about their views of giving medicines twice daily 
(grey shading) and how they thought things would change on once-daily. 12 and 48 weeks after 
moving to once-daily they were asked how they found the move. Questions about timing, number 
and taste of medications had three options Often, Sometimes or Never. A small number of 
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responses to specific questions were missing, n (%) are of those with available data. 
